Trial Profile
A double-blind, placebo-control, randomized phase III study to evaluate the efficacy and safety of TAC-202 in patients with perennial allergic rhinitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 May 2022
Price :
$35
*
At a glance
- Drugs Bilastine (Primary) ; Fexofenadine
- Indications Perennial allergic rhinitis
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 15 Jun 2015 Status changed from recruiting to completed.
- 13 Jan 2015 New trial record